TY - JOUR
T1 - Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma
AU - Kurihara, Momoko
AU - Kabata, Hiroki
AU - Irie, Misato
AU - Fukunaga, Koichi
N1 - Funding Information:
This work was supported by Keio University Academic Development Funds (to H.K.), grants from KAKENHI Grant-in-Aid for Scientific Research (C) (to H.K.), Mochida Memorial Foundation for Medical and Pharmaceutical Research Grant (to H.K.), and grants from KAKENHI Grant-in-Aid for Scientific Research (B) (to K.F.).
Publisher Copyright:
© 2022 Japanese Society of Allergology
PY - 2023/1
Y1 - 2023/1
N2 - Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, is the latest biologic for asthma. To evaluate the efficacy and mechanism of tezepelumab in asthma, the PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, and DESTINATION studies have been conducted. These results suggested that tezepelumab is a broad-target biologic, which is expected to be effective in patients with poorly controlled moderate to severe asthma regardless of the phenotype, although its efficacy in oral corticosteroids-dependent asthma, biological mechanism in non-type 2 phenotype, and long-term safety remain unknown. In this review, we summarize the results of clinical trials of tezepelumab in asthma and discuss the differences between tezepelumab and other biologics.
AB - Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, is the latest biologic for asthma. To evaluate the efficacy and mechanism of tezepelumab in asthma, the PATHWAY, NAVIGATOR, NOZOMI, UPSTREAM, CASCADE, SOURCE, and DESTINATION studies have been conducted. These results suggested that tezepelumab is a broad-target biologic, which is expected to be effective in patients with poorly controlled moderate to severe asthma regardless of the phenotype, although its efficacy in oral corticosteroids-dependent asthma, biological mechanism in non-type 2 phenotype, and long-term safety remain unknown. In this review, we summarize the results of clinical trials of tezepelumab in asthma and discuss the differences between tezepelumab and other biologics.
KW - Biologics
KW - ILC2s
KW - Randomized clinical trials
KW - Severe asthma
KW - Type 2 inflammation
UR - http://www.scopus.com/inward/record.url?scp=85143157279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143157279&partnerID=8YFLogxK
U2 - 10.1016/j.alit.2022.11.006
DO - 10.1016/j.alit.2022.11.006
M3 - Review article
C2 - 36470789
AN - SCOPUS:85143157279
SN - 1323-8930
VL - 72
SP - 24
EP - 30
JO - Allergology International
JF - Allergology International
IS - 1
ER -